Natalizumab Therapy for Moderate to Severe Crohn Disease in Adolescents

Abstract

Natalizumab (3 mg/kg) was well tolerated in these adolescent patients with active CD, with a safety and efficacy profile similar to that of adult natalizumab-treated CD patients. Future studies should evaluate long-term safety and efficacy.